All Articles

A $3M deal values Eye-Net's V2X tech at $55M, but the complex warrant structure tells a deeper story about Foresight's strategic play in road safety.

Fresh off a massive IPO, MapLight Therapeutics is racing toward pivotal data in schizophrenia and Alzheimer's. Can it defy the odds in biotech's riskiest field?

Beyond its third 'Global Bank of the Year' award, DBS is pioneering a future where AI protects customers and sustainability drives finance. What does this mean for us?

With nickel prices low, FPX Nickel is doubling down on its own stock. Is this a savvy capital move or a signal of a unique, undervalued asset?

With a BMO veteran on its board and a 1.5M oz gold project, junior miner Q-Gold signals a strategic shift from exploration to serious development.

RP1 is challenging tech's walled gardens by opening its spatial internet tools to all developers, aiming to build a truly decentralized and open metaverse.

By targeting Australia's resource sector, ZenaTech is betting big on its acquisition-led DaaS model. Here's what it means for the future of surveying.

With a ₹1000 crore backing, QWEEN is launching a 'self-discovery' retail model to challenge India's traditional, high-pressure luxury jewellery market.

With FDA clearance for a smarter algorithm, Insulet’s tubeless system promises tighter glucose control and fewer interruptions for users.

AMC CEO Adam Aron's minor stroke puts corporate governance to the test. The company's proactive disclosure offers a lesson in managing investor confidence.

In a volatile timber market, sophisticated investors are turning to granular data on sawmill operations to protect multi-million dollar construction projects.

New data shows UK workers are burnt out but enjoy their jobs. This resilience is a vital asset, but businesses are pushing it to its breaking point.

Beyond a simple equipment sale, Plug Power's deal with Hy2gen in France is a strategic move to build an entire hydrogen ecosystem in a key EU market.

Miami's recent tech summit unveiled ambitious plans for AI and quantum leadership. Can the state's new initiatives overcome infrastructure challenges?

A landmark $275M deal for a novel Hunter syndrome drug highlights a new frontier in treating brain diseases and a major shift in biotech funding.

uniQure’s promising gene therapy for Huntington's disease hits a major FDA roadblock, sending its stock tumbling and delaying hope for patients.

With new clinical data and major funding, PreciseDx's AI test aims to make breast cancer prognosis faster, cheaper, and more accurate than ever before.

As Halliburton elevates internal veterans, the move signals a calculated shift to fortify operations and empower long-term strategy in a volatile market.

A key leadership change at Light AI signals a critical shift from product development to market entry for its revolutionary smartphone diagnostic tech.

Iridium's appointment of tech veteran Louis Alterman to its board signals a strategic push into enterprise mobility and cloud-integrated satellite services.